retatrutide regulatory approval The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide, an experimental weight-loss drug,

Comparisons and related research compounds

Instead They Got Worse. Los Angeles Times, 15 Apr

However, the recommendation also stresses close monitoring, gradual reductions in insulin doses, maintaining adequate carbohydrate intake, ketone testing, sick-day rules and careful dose titration [4]

GLP-1 medications are powerful tools for weight loss, and with the right strategy, they can help you achieve long-term health goals while feeling your best

Based on the populations studied in clinical trials to date, retatrutide has been investigated primarily in adults living with obesity defined as a body mass index (BMI) of 30 kg/m or above as well as in those who are overweight (BMI 27 kg/m or above) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidaemia

Cloyd, J